Alpha memo: taurine supplementation

One-sentence alpha: Receipt 1 suggests taurine supplementation can blunt a cardio-metabolic risk factor (triglycerides) in high-caloric-fed Wistar rats, while Receipt 2 reframes taurine not as a one-way aid but as a biomarker whose deficiency may signal ageing, making the same molecule read as intervention in one context and as readout in another. Receipt 1: Effects of physical exercise and taurine supplementation on cardio‐metabolic risk factors in high caloric‐fed rats (2012) — in male Wistar rats on a 4-week high-caloric diet followed by 5 weeks of treadmill training (20 m/min, 60 min, 3×/week) and/or 2% taurine in drinking water, exercise or taurine per se reduced triglycerides, alongside an ~45% performance gain in trained groups. Receipt 2: Taurine as a biomarker for aging: A new avenue for translational research (2023) — argues that declining blood taurine (linked to loss of endogenous synthesis with age) may itself be a biomarker/driver of ageing, and that age-related multi-organ dysfunction has been associated with early-life taurine insufficiency, recasting taurine as a candidate ageing biomarker rather than a standalone supplement signal. Why this is surprising: Receipt 1 made plausible a clean, positive "more taurine = better cardio-metabolic profile" story; Receipt 2 updates that by treating taurine concentration as something that falls with ageing and may report biological age, so supplementation effects seen in a 9-week rat protocol may not cleanly transport to a lifespan/ageing frame and could be confounded by the very deficiency status Receipt 2 highlights. Caveats/falsifiers:

• Receipt 1 is a 9-week, n=20 male Wistar rat study using 2% taurine in water under a high-caloric diet; endpoints are limited to glucose, triglycerides, TBARS, and K_ITT — so the triglyceride reduction is bounded to this strain, dose, duration, and male-only cohort.
• Receipt 2 is a narrative/review framing rather than a direct interventional result, and explicitly invokes aging-related multi-organ endpoints in humans/mice that Receipt 1 never measured.
• Decisive future falsifier: a longitudinal intervention in aged animals (or humans) that raises blood taurine to youthful levels and fails to shift ageing-related biomarkers (or a trial showing the triglyceride benefit in Receipt 1 disappears once baseline taurine status is controlled for) would refute the assumption that Receipt 1's signal transports across the ageing context Receipt 2 introduces.